All posts by imreal

Population Health Alliance (PHA) Announces Center for Medicare and Medicaid innovation (CMMI) Keynote Speaker for PHA Expo 22


PHA Expo 22 https://phaexpo.com

“The Population Health Alliance holds CMMI’s mission to advance quality and affordability of healthcare in high regard,” said Rose Maljanian, Board Chairman Emeritus of PHA and Chairman & CEO of HealthCAWS.

Population Health Alliance (PHA), the industry’s only multi-stakeholder professional and trade association solely focused on population health, announced today that Kate Abowd Johnson, PhD of the Center for Medicare and Medicaid Innovation (CMMI) will join PHA as the luncheon keynote speaker on October 26th at the PHA Expo 22 in Washington DC. Ms. Johnson is the Acting Deputy Division Director for the Division of Population Health Incentives and Infrastructure at the Center for Medicare and Medicaid Innovation, which houses the Accountable Health Communities (AHC) and Integrated Care for Kids (InCK) Models. Kate previously led the AHC Model and has contributed to many population health and prevention models and Social Determinants of Health initiatives at the Innovation Center since joining in 2016. Prior to that she worked at Johns Hopkins University, where her research focused on neighborhood impacts on obesity and associated chronic disease, and in management consulting. Kate holds a PhD in Social and Behavioral Sciences from Johns Hopkins University, an MS in Nutrition with a specialization in Food Policy from Tufts University, and a BBA from the University of Notre Dame.

“The Population Health Alliance holds CMMI’s mission to advance quality and affordability of healthcare in high regard,” said Rose Maljanian, Board Chairman Emeritus of PHA and Chairman & CEO of HealthCAWS. “PHA is honored to welcome Ms. Johnson as keynote speaker given her vast knowledge and breath of the areas she covers that are important to PHA including advancing value based care, social determinants of health, and health equity,” she added.

The PHA Expo 2022-Decision Maker’s Connect” will focus on marketplace needs that improve the consumer journey and health, achieve quality of care targets, reduce costs and advance technologies to improve efficiency and relieve burdens from an already stretched workforce. The intimate environment will allow audience members to meet directly with PHA Board members and senior leadership colleagues to advance current and future partnerships.

The interactive sessions and networking opportunities will include:

  • CMMI Priorities and Strategies
  • Medicaid- Population Health Needs Amidst Growing Challenges
  • Senior Health-Ramping Up Aging in Place Support
  • Employer Value-based Approaches to Benefit Design and Health Promotion
  • Advanced Analytics Across Market Segments
  • Public Private Partnerships to Achieve Community Health

Across these market focused sessions topical issues such as chronic condition prevention and management, addressing the growing behavioral health crisis, and supports for social determinants of health and health equity will be addressed. To review the entire agenda and register for the PHA Expo 22 please visit Https://phaexpo.com/

About Population Health Alliance

Established in 1998, Population Health Alliance (PHA) is the industry’s only multi-stakeholder professional and trade association solely focused on population health management, representing stakeholders (e.g., health systems, health plans, employer solutions, academia, biopharma and technology companies) from across the health care ecosystem that seek to improve health outcomes optimize the consumer and provider experience and drive affordability. Learn more at http://www.populationhealthalliance.org . Join us at PHA Expo 22 https://phaexpo.com

.

About the Center for Medicare and Medicaid innovation (CMMI)

The Centers for Medicare & Medicaid Services (CMS) Innovation Center, also known as “CMMI,” develops and tests new healthcare payment and service delivery models to: improve patient care; lower costs; and better align payment systems to promote patient-centered practices.

The CMS Innovation Center tests alternative payment models (APMs) which reward health care providers for novel approaches to delivering cost-efficient, high-quality care. APMs can apply to a specific:

  • Health condition, like end-stage renal disease.
  • Care episode, like joint replacement.
  • Provider type, like primary care providers.
  • Community, like rural areas.
  • Innovation within Medicare Advantage or Medicare Part D.

The CMS Innovation Center was established by Congress in 2010 to identify ways to improve healthcare quality and reduce costs in the Medicare, Medicaid, and Children’s Health Insurance Program (CHIP) programs. Following this charge, the CMS Innovation Center, through its models, initiatives and Congressionally-mandated demonstrations, has accelerated the shift from a health care system that pays for volume to one that pays for value.

Share article on social media or email:

Jacob Biedinger’s newly released “Herbie, The Turtle Who Wished He Could Fly” is an entertaining children’s tale that encourages embracing one’s uniqueness.


News Image

“Herbie, The Turtle Who Wished He Could Fly”: a vibrant juvenile fiction with an important message. “Herbie, The Turtle Who Wished He Could Fly” is the creation of published author Jacob Biedinger, a United States Marine Corps veteran who enlisted in 1958.

Biedinger shares, “Herby, The Turtle Who Wished He Could Fly is a fun and easy-to-read children’s story about realizing your personal strengths.

“It’s easy to perceive someone else’s achievements or abilities as being better than your own, but everyone has something they excel at. After spending most of his time wishing he could fly, Herby learns that his swimming skill is equally special and unique to him.

“When faced with disaster, Herby uses the very thing he took for granted to become a hero. It’s a wonderful lesson for any age, delivered in rhyme and beautifully illustrated. Intended to encourage the audience by focusing less on shortcomings and discovering that we all have something that makes us special and unique.”

Published by Christian Faith Publishing, Jacob Biedinger’s new book features charming illustrations created by Shannon Bost.

Biedinger shares in hopes of helping young minds to focus on their strengths and work past their shortcomings.

Consumers can purchase “Herbie, The Turtle Who Wished He Could Fly” at traditional brick & mortar bookstores, or online at Amazon.com, Apple iTunes store, or Barnes and Noble.

For additional information or inquiries about “Herbie, The Turtle Who Wished He Could Fly,” contact the Christian Faith Publishing media department at 866-554-0919.

Share article on social media or email:

Candice Gaddy’s newly released “Healing Stitches” is an inspiring biographical work that expresses a powerful message for those going through challenging phases


News Image

“Healing Stitches”: a hopeful message of God’s healing promise. “Healing Stitches” is the creation of published author Candice Gaddy, a continual life learner with a bachelor’s degree in finance/marketing, a licensed certified coach, a master’s in executive leadership, a Six Sigma Black Belt process certified, a certified capital lender, a licensed health/life insurance advisor, and over twenty years of Fortune 500 Corporate leadership.

Gaddy shares, “Author Candice Gaddy shares her upbringing in a Christian single-parent home only later to realize she never really knew God for herself. In this true-life story, it took her losing everything, coming close to death multiple times, literally losing her mind with a stroke/brain hemorrhage to learn to trust God and the process of healing! Every new phase in life you must heal from the prior to be ready for the new level. The reader will not only hear from real-life experiences but understand from true biblical references how we are equipped to turn every battle scar into a weapon to defeat the enemy. There is no season of healing you cannot overcome whether financial, physical, mental, or emotional. Natural remedy doctors will tell you that often the best medicine is natural or just simply allowing the body to heal. As you read, sit still and ‘know that I am God’ is what he is trying to tell you during your healing uncertainty!”

Published by Christian Faith Publishing, Candice Gaddy’s new book takes readers into a deeply personal journey of healing that presents readers with heartfelt encouragement.

Gaddy’s enthusiasm and determination are a welcome message for readers facing the valleys of life.

Consumers can purchase“Healing Stitches” at traditional brick & mortar bookstores, or online at Amazon.com, Apple iTunes store, or Barnes and Noble.

For additional information or inquiries about “Healing Stitches,” contact the Christian Faith Publishing media department at 866-554-0919.

Share article on social media or email:

Radsource Adds 8 ProtonPACS Customers in the Second Quarter of 2022


Nashville, Tenn. – Radsource, a leader in radiology clinical services and provider of Picture Archiving and Communication Systems (PACS), completed 8 installations of ProtonPACS for new customers in the second quarter of 2022.

In Q2, Radsource installed ProtonPACS at a surgery center in Florida, a health center in Michigan, and a vascular medicine practice in California, among other medical imaging facilities across the country.

Based in Victorville, Vascular Associates of Southern California (VASC) is a multi-provider vascular medical practice with four locations in the SoCal region. When this growing practice determined it was time to implement their own PACS, they selected ProtonPACS and went live with the installation in July 2022.

“The technical support we have received from the Radsource team has been exceptional,” says Julia Mauro, general manager of VASC. “ProtonPACS has provided us with secure on-site storage, easy access to our patient’s imaging, and the ability for our clinicians to create custom reports with ease. They have worked diligently to create a customized workflow that addresses the needs of our practice.”

About Radsource

Radsource is a nationwide leader in MRI interpretation and PACS development. Building on its clinical success in MRI interpretation, Radsource developed ProtonPACS, a PACS specifically engineered to overcome the challenges users face with other systems. ProtonPACS provides hospitals, imaging centers and physician practices advanced tools to optimize imaging workflow and increase profitability. The company is uniquely positioned to provide expertise in all aspects of medical imaging.

Share article on social media or email:

First-Ever CPESN® Celebration Award Winners Announced at PioneerRx Connect


“CPESN pharmacies are allowing pharmacy technicians to see their work not just as a job, but as a career.”

CPESN USA, a clinically integrated, nationwide organization of pharmacy networks created to advance community-based pharmacy practice, announced the winners of the 2022 CPESN® Celebration Awards. We were able to recognize eight CPESN pharmacies from all over the country in an effort to reward them for their continued pharmacy services efforts in their local communities. The following pharmacies were recognized:

COVID-19 Immunizations Award

Carvajal Pharmacy

San Antonio, Texas

CPESN Texas

eCare Planning Award

Panama Pharmacy

Jacksonville, Florida

CPESN Florida

Founders Award

Osterhaus Pharmacy

Maquoketa, Iowa

CPESN Iowa

Opioid Safety Award

Sumrall Drug Store

Sumrall, Mississippi

CPESN Mississippi

Quality-Focused Pharmacy Award

Klingensmith’s Pharmacy

Ford City, Pennsylvania

PPCN – CPESN Pennsylvania

Quality-Focused Pharmacist Award

Brenna Neuman, Collier Drug

Fayetteville, Arkansas

Arkansas CPESN

Pharmacist MVP Award

Michelle Farrell, Boscobel Pharmacy

Boscobel, Wisconsin

CPESN Wisconsin

Pharmacy Technician MVP Award

Sirena Kalinski, Duvall Family Drugs

Duvall, Washington

CPESN Washington

“We are honored to have these outstanding pharmacists, technicians, and pharmacy providers as active participants of local CPESN Networks across America,” said Troy Trygstad, PharmD, MBA, PhD, Executive Director of CPESN USA. “The effort these award-winners made to improve the health of their local communities deserves to be recognized.”

The CPESN Celebration was a part of the agenda of activities at the PioneerRx Connect Conference held last month in Nashville. All of the pharmacies recognized are participating in CPESN Networks and using PioneerRx or QS/1 as their pharmacy management system.

“I am so excited about being selected for this year’s Pharmacy Technician MVP Award!” shared Sirena Kalinski, with Duvall Family Drugs in Duvall, Washington. “CPESN pharmacies are allowing pharmacy technicians to see their work not just as a job, but as a career.”

About CPESN® USA

CPESN® USA a clinically integrated, nationwide organization of pharmacy networks structured to advance community-based pharmacy practice. They empower community-based pharmacies that are deeply rooted within their community by fostering their ability to provide high quality, patient-centered enhanced services. CPESN® pharmacies integrate with other healthcare providers on the patient’s care team to coordinate medical treatment. The results are better medication adherence, higher patient satisfaction, and lower healthcare costs. You can find CPESN® Networks of pharmacy providers in 42 states across America. To learn more, please visit http://www.CPESN.com.

Share article on social media or email:

NovaBone Welcomes Medical Device Expert to Their Leadership Team


Novabone Announces New CEO

Leaders in biologic medical devices, NovaBone, has today announced Brian Carlisle as the company’s new CEO. With a focus on developing biomaterials that harness the body’s natural healing process and meeting the specialized needs of orthopedic and dental surgeons, the addition of Mr. Carlisle will play a critical role in the continued growth of the organization.

Carlisle has an extensive career in the medical device industry, with 17 years of experience. He has worked with organizations such as Integra LifeSciences and Perma Pure LLC, mastering his skills in operations, sales, business process improvement, marketing, and much more.

Before taking on the role of CEO, Brian held a position on NovaBone’s Board of Directors for 10 months, working towards building the brand and generating momentum for the company.

“Since joining NovaBone, I have noticed many impressive qualities that permeate throughout the organization. First, there is an energy and passion amongst our people and a collective mindset that is focused on the patients we serve. There is also a strong comradery amongst our employees which creates an environment where everyone feels welcomed and accepted. Moving forward, I am excited to see NovaBone leverage our resources and capabilities in bioactive glass and collagen manufacturing to bring new technology to market as we continue the journey to improve patient outcomes.” – Brian Carlisle, NovaBone CEO

As the new CEO, Brian will use his extensive leadership and management skills to further enhance the growth of NovaBone, improve customer experiences, and reach new markets.

For more information on Mr. Carlisle and his new position, visit NovaBone.com.

About NovaBone

NovaBone is a privately held company based in Florida since 2002. NovaBone developed the first bioactive synthetic bone graft offered to the orthopedic community and has long been at the forefront of bioactive glass bone graft devices. It has developed numerous formulations and delivery systems of its patented, bioactive technology platform that results in accelerated bone growth.

In total, their exclusively formulated bone graft substitute has been used for the repair of osseous defects throughout the skeletal system for over a decade and used in over a million clinical applications with unparalleled success validating the safety and efficacy of NovaBone’s technology.

Share article on social media or email:

Shady Grove Fertility (SGF) Tampa Bay physicians recognized as 2022 Top Doctors for Infertility by Tampa magazines


SGF Tampa Bay physicians, Drs. Imudia, Plosker, and Silva, honored as Top Docs for Infertility by Tampa magazines.

“Being recognized within our community for this patient-centered approach is a true honor I am proud to be in company with my fellow SGF Tampa Bay physicians and many other esteemed physicians.”

Shady Grove Fertility (SGF) Tampa Bay is proud to announce that physicians Anthony N. Imudia, M.D., Celso Silva, M.D., and Shayne Plosker, M.D., have been named Tampa magazines’ Top Doctors for Infertility.

In March, Tampa magazines sent surveys to more than 9,000 physicians practicing in Hillsborough, Pinellas, and Pasco counties asking them to nominate the peers they believe stand out from the rest. The annual Top Doctors edition includes all four publications —TAMPA Magazine, South Tampa Magazine, TAMPA Downtown Magazine, and TAMPA Digest Magazine — for a total circulation of 60,000.

“SGF Tampa Bay believes in fostering a culture of excellence in fertility care for our patients,” shares Dr. Imudia. “Being recognized within our community for this patient-centered approach is a true honor I am proud to be in company with my fellow SGF Tampa Bay physicians and many other esteemed physicians.”

SGF Tampa Bay provides a full range of diagnostic and treatment options complete with a premier IVF laboratory to help individuals and couples achieve their family-building goals. The regional practice offers three convenient offices in Brandon, Tampa – Westshore, and Wesley Chapel. SGF Tampa Bay will also be opening a new office in St. Petersburg later this summer.

“I am truly honored to be recognized by my peers as a Top Doctor for Infertility,” shares Dr. Silva. “Providing affordable, accessible fertility care makes a difference in the lives of the 1 in 8 couples who will experience infertility. SGF’s innovative financial plans make treatment more affordable and truly reiterate our ‘patients come first’ mentality.”

SGF Tampa Bay proudly offers the Shared Risk 100% Refund Program. This exclusive program provides patients with the opportunity to pay a fixed amount for up to six fresh IVF or donor egg cycles and any subsequent frozen embryo transfers (FETs). Of the total Shared Risk 100% Refund Program participants, 82 percent take home a baby, and the rest receive a full refund to use for other family-building options.

“I am humbled to be recognized by Tampa magazines as a Top Doctor for Infertility,” shares Dr. Plosker. “It is truly an honor to be a part of my patients’ family-building journeys.”

For people struggling to conceive, it may be time to consult a fertility specialist. Contact the SGF New Patient Center at 1-888-761-1967 or complete a brief online request form to schedule a consult with an SGF physician. A physician consult is the first step toward pursuing a pregnancy with the help of SGF.

About Shady Grove Fertility (SGF)

SGF is a leading fertility and IVF center of excellence with more than 100,000 babies born from 30+ years of continuous innovation and patient-centered fertility care. With 46 locations, including new locations in Texas, as well as throughout CO, FL, GA, MD, NY, PA, TX, VA, D.C., and Santiago, Chile, SGF offers patients in-person and virtual physician consults, delivers individualized care, accepts most insurance plans, and makes treatment affordable through innovative financial options, including 100% refund guarantees. SGF is among the founding partner practices of US Fertility, the largest physician-led partnership of top-tier fertility practices in the U.S. Call 1-888-761-1967 to schedule a new patient appointment or visit ShadyGroveFertility.com for more information.

Share article on social media or email:

AHN Specialists Studying New Treatment for Relapsing Multiple Sclerosis


News Image

“For those who live with multiple sclerosis and the knowledge that their disease will eventually rob them of the ability to function independently, the more options we can provide them to slow the disease process and allow them to live a somewhat normal life, the better,” said Dr. Desai.

Doctors at Allegheny Health Network (AHN), led by neurologist Troy Desai, MD, are exploring the use of a new drug to treat relapsing or primary progressive multiple sclerosis (MS). AHN is one of 276+ worldwide participating in the FENhance study, a Phase III clinical trial to assess the safety and efficacy of the drug Fenebrutinib compared to an approved comparator drug for the condition.

MS is a disease that occurs when the body’s immune system malfunctions, attacking the brain, spinal cord and optic nerves of the central nervous system. It is the leading cause of nervous system-related disability in young people, usually striking between 20 and 40 years of age. In the United States, approximately one million people have MS, with women two to three times more likely to develop the condition than men.

One of the drugs in this study, Fenebrutinib, is designed to enter the central nervous system to block the activity of Bruton’s tyrosine kinase, an enzyme that plays a key role in activating the B-cells that can trigger an inflammatory immune response. The other drug, teriflunomide, has already been tested and FDA approved for the treatment of multiple sclerosis and has been available to people with MS since 2013.

“Symptoms of MS are unpredictable, and include numbness, tingling, mood changes, memory problems, pain, fatigue, blindness and paralysis,” said Dr. Desai. “Everyone’s experience with MS is unique and the symptoms may be temporary or long lasting and ultimately debilitating.”

Clinical evidence shows that MS progresses even when the patient is not exhibiting symptoms; MRI scans and cognitive tests usually reveal increased disease activity even when the patient appears to be in remission.

Studies conducted years ago showed that about half of the people with MS needed a cane to walk within 10 to 15 years of their diagnosis. However, this was before the advent of disease modifying medications to treat multiple sclerosis. These days, the risk of needing a cane is much lower, but not zero, according to Dr. Desai.

“Our treatments are very effective at reducing the chance of sudden changes called relapses or attacks of MS,” said Dr. Desai. “However, they are less effective at preventing progression, which is a gradual worsening that occurs over months or years and impact a person’s ability to walk and care for themselves and their family.”

While many treatments have been approved for RMS, there remains an unmet need for more effective medications that may not only reduce MS disability and relapses but slow the progression of the disease. “That’s the purpose of this study,” said Dr. Desai. “We want to see if the investigational study drug, Fenebutrinib, can be a safe, but more effective option than the one currently in use.”

The global FENhance study will involve 1400 total participants between the ages of 18 and 55 who have been diagnosed with RMS within the last 10 years; AHN will enroll at least 4 such participants. The blind randomized study will be divided into two groups; one group will receive the investigational drug, Fenebutrinib while the other group receives the comparator drug, Teriflunomide.

“For those who live with multiple sclerosis and the knowledge that their disease will eventually rob them of the ability to function independently, the more options we can provide them to slow the disease process and allow them to live a somewhat normal life, the better,” said Dr. Desai. “There is still much to learn about MS and even more to discover about how best to treat it, but this study represents a significant step in the right direction.”

Those interested in learning more about the FENhance study can call the study coordinator Mary Fetter at 412-359-4856 or email: mary.fetter@ahn.org.

###

About the Allegheny Health Network:

Allegheny Health Network (AHN.org), a Highmark Health company, is an integrated healthcare delivery system serving the greater Western Pennsylvania region. The Network is composed of 13 hospitals, ambulatory surgery centers, Health + Wellness Pavilions, an employed physician organization, home and community-based health services, a research institute, and a group purchasing organization. The Network provides patients with access to a complete spectrum of advanced medical services, including nationally recognized programs for primary and emergency care, trauma care, cardiovascular disease, organ transplantation, cancer care, orthopedic surgery, neurology and neurosurgery, women’s health, diabetes, autoimmune disease and more. AHN employs approximately 21,000 people, has more than 2,500 physicians on its medical staff and serves as a clinical campus for Drexel University College of Medicine and the Lake Erie College of Osteopathic Medicine.

Share article on social media or email:

Aria Care Partners Hires Chief Medical Officer To Focus on Audiology Care


“We are excited to have Dr. Sporn join the team and lead our expansion into Audiology Services,” says John Griscavage, CEO of Aria Care Partners. “She has the compassion and experience that will benefit our organization and the individuals we serve across the nation.”

Leading provider of integrated ancillary medical services hires Chief Medical Officer to focus on audiology care.

Aria Care Partners, the leading provider of ancillary medical services for skilled nursing facilities, has announced Michelle T. Sporn, Au.D., ABAC, as chief medical officer of its Audiology service line. She officially began the position June 20, 2022.

Dr. Sporn is an American Board of Audiology certified audiologist with an extensive background in audiology including serving in a leadership role at Starkey Hearing Technologies. In addition, she has held positions with the U.S. Department of Veterans Affairs, supporting the Veterans Benefits Administration, and the Silverstein Institute.

She has a doctorate of audiology from Salus University, Elkins Park, PA (formerly Pennsylvania College of Optometry (PCO) School of Audiology). Dr. Sporn graduated cum laude with an undergraduate degree in communication sciences and disorders from the University of Florida, Gainesville, FL.

“We are excited to have Dr. Sporn join the team and lead our expansion into Audiology Services,” says John Griscavage, CEO of Aria Care Partners. “She has the compassion and experience that will benefit our organization and the individuals we serve across the nation.”

Dr. Sporn’s primary focus is to provide support and guidance to the Aria Care Partners team of audiologists. She will also set policies and procedures to provide quality audiological care for residents in long-term care facilities.

About Aria Care Partners

Aria Care Partners is the leading provider of onsite ancillary medical services for skilled nursing facilities. With more than 20 years of partnership with nearly 3,000 skilled nursing facilities, Aria Care Partners remains on the leading edge of innovative care delivery, understanding the connection between dental, vision, and hearing services to resident health and well-being. With a unique combination of turnkey insurance solutions and innovative service delivery, Aria Care Partners is passionate about enriching every resident’s quality of life and ensuring that every family knows their loved ones are well cared for and safe.

Share article on social media or email:

Genscript to Host their 2nd “Gene and Cell Engineering Summit,” July 28, 2022


Genscript to Host their 2nd “Gene and Cell Engineering Summit,” July 28, 2022

Genscript to host their 2nd “Gene and Cell Engineering Summit” on July 28th 2022, on the Labroots platform.

At Genscript’s Virtual Summit, expect to see leaders in the life sciences from academia, pharma, and biotech, leveraging the strengths of synthetic biology technologies to develop life-changing therapies. Join GenScript at this one-day event featuring keynote presentations and two tracks dedicated to invited speakers working on Cell Therapy or Gene Therapy research.

Topics include:

  • How synthetic biology continues to revolutionize life science research
  • Advancing gene and cell therapies
  • Efficient development of invaluable biotherapeutics for various human diseases

To register for the event, and view the agenda, click here.

About Genscript

GenScript, a leading contract research organization (CRO), provides a one-stop solution to investigators globally working with genes, peptides, proteins, CRISPR tools, and antibodies. Since its foundation 20 years ago, GenScript has grown exponentially through strategic capacity expansions, licensing agreements for accessing cutting-edge technologies, and partnerships with scientists conducting basic life science investigation, translational biomedical research, and early-stage pharmaceutical development. GenScript is recognized as having built a best-in-class capacity and capability for biological research services, encompassing gene synthesis, peptide synthesis, custom antibody, and protein engineering. Deep commitment, expertise, and innovative approaches to synthesizing high-quality genes have enabled GenScript to become a leader in the Gene and Cell Engineering space. Resolute in its goal to Make Research Easy, today, GenScript provides complete solutions to investigators developing cell therapies through viral or fully non-viral CRISPR strategies. For more information, please visit http://www.genscript.com.

About Labroots

Labroots is the leading scientific social networking website and primary source for scientific trending news and premier educational virtual events and webinars and more. Contributing to the advancement of science through content sharing capabilities, Labroots is a powerful advocate in amplifying global networks and communities. Founded in 2008, Labroots emphasizes digital innovation in scientific collaboration and learning. Offering more than articles and webcasts that go beyond the mundane and explore the latest discoveries in the world of science, Labroots users can stay atop their field by gaining continuing education credits from a wide range of topics through their participation in the webinars and virtual events.

Share article on social media or email: